Results 81 to 90 of about 1,703,276 (117)

Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer

open access: yesNew England Journal of Medicine, 2017
K. Fizazi   +14 more
semanticscholar   +1 more source

Caractérisation statistique des redoux : Application à quatre stations de la province de Québec. [PDF]

open access: yes, 2004
Benyahya, Loubna   +4 more
core  

Lois de Halphen: méthodes d'estimation mixtes et comparaison. [PDF]

open access: yes, 2008
Bobée, Bernard   +2 more
core  
Some of the next articles are maybe not open access.

Related searches:

Frequency analysis of rainfall events in Karbala city, Iraq, by creating a proposed formula with eight probability distribution theories

Smart Science, 2023
Due to its impact on the derivation of hydrological models and the safe design of sewer and storm networks, the anticipation of rainfall events should be intensively studied.
A. T. Al-Awadi   +2 more
semanticscholar   +1 more source

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

New England Journal of Medicine, 2023
BACKGROUND No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy. METHODS In this phase 3, multinational, open-label trial, we randomly assigned
M. S. van der Heijden   +23 more
semanticscholar   +1 more source

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

NEJM Evidence, 2022
Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin.
D. Oh   +28 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy